Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran

Hepatitis Monthly

Volumn 7, Issue 2, 2007, Pages 63-66

  Akbari, Ahmad ^a   Imanieh, Mohammad Hadi ^b   Karimi, Mehran ^c   Tabatabaee, Hamid Reza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood bank; Blood transfusion; HCV; Iran; Thalassemia

Indexed keywords

DEFEROXAMINE MESYLATE; FERRITIN; HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NONHUMAN; QUESTIONNAIRE; RISK FACTOR; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR;

EID: 44949132028     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Wonke B, Hoffbrand AV, Bouloux P, Jensen C, Telfer P. New approaches to the management of hepatitis and endocrine disorders in Cooley’s anemia. Ann N Y Acad Sci 1998; 850: 232-41.
2. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. Int J Infect Dis 2006; 10: 272-7.
3. Rodis J. Chronic hepatitis C virus infection: a review for pharmacists. J Am Pharm Assoc (2003) 2007; 47: 508-20.
4. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med 2006; 9: 319-23.
5. Di MV, Lo IO, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in betathalassemics with chronic hepatitis C. Blood 1997; 90: 2207-12.
6. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent betathalassemia. A multicenter study of 117 cases. Haematologica 2004; 89: 1179-86.
7. Prati D, Zanella A, Farma E, De MC, Bosoni P, Zappa M, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998; 92: 3460-4.
8. Zurlo MG, De SP, Borgna-Pignatti C, Di PA, Piga A, Melevendi C, et al. Survival and causes of death in thalassemia major. Lancet 1989; 2: 27-30.
9. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of posttransfusion hepatitis C virus infection. N Engel J Med 1992; 327: 369-73.
10. Franchini M, Rossetti G, Tagliaferri A, Capra F, de ME, Pattacini C, et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 2001; 98: 1836-41.
11. Aoki SK, Holland PV, Fernando LP, Kuramoto IK, Anderson S, Sazama K, et al. Evidence of hepatitis in patients receiving transfusions of blood components containing antibody to hepatitis C. Blood 1993; 82: 1000-5.